Using flow-cytometry in measuring platelet activity in type 2 diabetes and predicting macrovascular complications … Original Research Article … |
The Egyptian Journal of Immunology E-ISSN (2090-2506) Volume 32 (1), January 2025 Pages: 01–15. www.Ejimmunology.org https://doi.org/10.55133/eji.320101 |
|
Mai M. Aly1, Hanaa M. Mohamed2, Fatema A. EL-Osily3, Eman R. Badawy4, Mohamed M. Shehab5, Mohammad H. AbdEllah-Alaui3, and Dina A. Hamad6 |
1Clinical Hematology Unit, Department of Internal Medicine, Faculty of Medicine, Assiut University, Assiut, Egypt.
2Department of Internal Medicine, Abu-tig Model Hospital, Ministry of Health-Specialized Medical Centers, Assiut, Egypt. 3Department of Internal Medicine, Faculty of Medicine, Assiut University, Assiut, Egypt. 4Department of Clinical Pathology, Faculty of Medicine, Assiut University, Assiut, Egypt. 5Department of Neuropsychiatry, Faculty of Medicine, Assiut University, Assiut, Egypt. 6Critical Care unit, Department of Internal Medicine, Faculty of Medicine, Assiut University, Assiut, Egypt. |
Corresponding author: Eman R. Badawy, Department of Clinical Pathology, Faculty of Medicine, Assiut University, Assiut, Egypt. Email: e.badawy@aun.edu.eg. |
Abstract
Platelets are hyperactive in patients with type2 diabetes (T2DM), they adhere to vascular endothelium and play a key role in macrovascular complications. Platelets activity can be measured by flow-cytometry (cluster of differentiation (CD) 41, CD 42, CD 62, CD 63), which allows detection of surface antigens in a sensitive and specific manner. This study aimed to describe platelets activity in T2DM in association with cardiovascular and cerebrovascular complications in relation to duration of diabetes (DM). This was a case-control study with 130 participants (65 diabetic cases and 65 normal controls). All cases were subjected to history and clinical examination, base-line laboratory investigations and surface expression of platelets receptors e.g. CD 41% and mean fluorescent intensity (MFI), CD 42% and MFI, CD 62% and MFI, CD 63% and MFI were determined by flow-cytometry. There was a statistically significant higher expression of CD 62%, CD 62 MFI, CD 63% and CD 63 MFI (p<0.001 for all) in diabetic cases compared to controls. There were significantly higher CD 62 %, CD 62 MFI, CD 63% and CD 63 MFI in cases with cardiovascular complications (p=0.001, p<0.001, p=0.05 and p=0.007, respectively) and in cases with cerebrovascular complications compared to cases without complications (p=0.05, p=0.008, p=0.035, p=0.017, respectively). A significant positive correlation was found between glycated hemoglobin, body mass index and CD 62 %, CD 62 MFI and CD 63%. Using the receiver operating characteristic curve showed that CD 62 %, CD 62 MFI, CD 63 % and CD 63 MFI have a diagnostic ability to early predict DM (area under the curve (AUC)=0.998) as well as cardiovascular (AUC=0.855) and cerebrovascular (AUC=0.765) complications. In conclusion CD 62%, CD 62 MFI, CD 63% and CD 63 MFI markers have a diagnostic ability for early prediction of cardiovascular and cerebrovascular complications among diabetic patients.
Keywords:
Platelet activity, Cardiovascular complication, Cerebrovascular complication.
Date received:
24 January 2024; accepted: 04 September 2024
PMID:
39803851
Full Text